Photo from wikipedia
Key Points Question Is there a difference in survival or toxic effects between the main first-line therapies used for metastatic pancreatic cancer? Findings In this comparative effectiveness study that included… Click to show full abstract
Key Points Question Is there a difference in survival or toxic effects between the main first-line therapies used for metastatic pancreatic cancer? Findings In this comparative effectiveness study that included 1102 patients, FOLFIRINOX (combined leucovorin calcium [folinic acid], fluorouracil, irinotecan hydrochloride, and oxaliplatin) was associated with improved survival of approximately 2 months compared with gemcitabine plus nab-paclitaxel and fewer posttreatment hospitalizations. Meaning Clinical data suggest that FOLFIRINOX should be the preferred first-line treatment for metastatic pancreatic cancer.
Journal Title: JAMA Network Open
Year Published: 2022
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!